[1]陈 添.不同剂量布地奈德雾化吸入对老年慢性阻塞性肺病急性加重期患者的治疗效果观察[J].医学信息,2025,38(13):98-102.[doi:10.3969/j.issn.1006-1959.2025.13.018]
　CHEN Tian.Observation on the Therapeutic Effect of Different Doses of Budesonide for Aerosol Inhalationon Elderly Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2025,38(13):98-102.[doi:10.3969/j.issn.1006-1959.2025.13.018]
点击复制

不同剂量布地奈德雾化吸入对老年慢性阻塞性肺病急性加重期患者的治疗效果观察()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年13期
页码:
98-102
栏目:
论著
出版日期:
2025-07-01

文章信息/Info

Title:
Observation on the Therapeutic Effect of Different Doses of Budesonide for Aerosol Inhalationon Elderly Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1006-1959（2025）13-0098-05
作者:
陈 添
会昌县人民医院急诊科，江西 会昌 342600
Author(s):
CHEN Tian
Department of Emergency, Huichang County People’s Hospital, Huichang 342600, Jiangxi, China
关键词:
不同剂量; 布地奈德; 雾化吸入; 老年; 慢性阻塞性肺病急性加重期
Keywords:
Different dose;  Budesonide;  Aerosol inhalation;  Elderly;  Acute exacerbation of chronic obstructive pulmonary disease
分类号:
R563
DOI:
10.3969/j.issn.1006-1959.2025.13.018
文献标志码:
A
摘要:
目的 探讨不同剂量布地奈德雾化吸入对老年慢性阻塞性肺病急性加重期患者的治疗效果。方法 采用随机数字表法将2021年1月-2024年1月我院收治的80例老年慢性阻塞性肺病急性加重期患者分为对照组和研究组，每组40例。对照组吸入用布地奈德混悬液雾化治疗为常规剂量（1 mg/次），研究组布地奈德混悬液雾化吸入溶液治疗为大剂量（2 mg/次）。比较两组临床疗效、肺功能[第1秒用力呼吸气量（FEV1）、用力肺活量（FVC）、FEV1/FVC、呼气峰值流速（PEF）]、炎性因子[白细胞介素-8（IL-8）、肿瘤坏死因子-ɑ（TNF-ɑ）、降钙素原（PCT）]、免疫功能（CD3+、CD4+、CD8+、CD4+/CD8+）、不良反应（头晕、口干、心悸、便秘）发生率。结果 研究组治疗总有效率，治疗后FEV1、FVC、FEV1/FVC及PEF水平均高于对照组（P＜0.05）。研究组IL-8、TNF-ɑ及PCT水平均低于对照组（P＜0.05）。研究组CD3+、CD4+及CD4+/CD8+水平均高于对照组，CD8+水平低于对照组（P＜0.05）。两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 大剂量（2 mg/次）布地奈德雾化吸入治疗老年慢性阻塞性肺病急性加重期患者的效果确切，对患者肺功能及免疫功能改善效果较好，能缓解机体炎症反应，减少不良反应，值得临床应用。
Abstract:
Objective To investigate the therapeutic effect of different doses of budesonide for aerosol inhalation on elderly patients with acute exacerbation of chronic obstructive pulmonary disease. Methods Using the random number table method, totally 80 elderly patients with acute exacerbation of chronic obstructive pulmonary disease admitted to Huichang County People’s Hospital during the period from January 2021 to January 2024 were randomly allocated into a control group and an study group, each consisting of 40 patients. The control group was treated with conventional dose（1 mg/times） of budesonide suspension for inhalation, and the study group was treated with large dose （2 mg/times）of budesonide suspension for inhalation. The clinical efficacy, lung function [ forced expiratory volume in one second (FEV1), forced vital capacity (FVC), FEV1/FVC, peak expiratory flow (PEF)], inflammatory factors [interleukin-8 (IL-8), tumor necrosis factor-ɑ (TNF-ɑ), procalcitonin (PCT)], immune function (CD3+, CD4+, CD8+, CD4+/CD8+), and incidence of adverse reactions (dizziness, dry mouth, palpitation, constipation) were compared between the two groups. Results Compared with control group, the study group had a higher total response rate, as well as the levels of FEV1, FVC, FEV1/FVC ratio and PEF after treatment (P<0.05). The levels of IL-8, TNF-α, and PCT were lower in the study group than those in the control group (P<0.05). Additionally, the study group showed significantly higher CD3+, CD4+, and CD4+/CD8+ levels, and lower CD8+ levels than those in the control group (P<0.05). No statistically significant difference was observed in adverse reaction rates between the groups (P>0.05). Conclusion High-dose (2 mg/times) budesonide for aerosol inhalation is effective in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease, which can improve the lung function and immune function of patients, alleviate the inflammatory response of the body, and reduce adverse reactions. It is worthy of clinical application.

参考文献/References:

[1]李冲,高俊杰,王红月,等.布地奈德福莫特罗粉吸入剂联合孟鲁司特治疗老年慢阻肺哮喘重叠综合征患者的疗效[J].中国煤炭工业医学杂志,2023,26(1):108-112.[2]谷亮,吴波.高通量测序下吸入性糖皮质激素对老年慢阻肺患者痰液微生物组学的影响研究[J].贵州医药,2021,45(5):745-746.[3]赵宁,谭楠,刘婷婷.布地奈德雾化联合胸腺肽α-1治疗哮喘慢阻肺重叠综合征临床效果及对患者血清炎症因子影响分析[J].陕西医学杂志,2018,47(7):927-930.[4]武焕龙.盐酸氨溴索治疗老年慢性阻塞性肺疾病合并肺部感染疗效与药物不良反应[J].山西医药杂志,2021,50(6):966-968.[5]李继霞,米晶晶.布地奈德福莫特罗粉吸入剂联合复方异丙托溴铵溶液雾化用于慢阻肺并发肺动脉高压的临床研究[J].贵州医药,2023,47(2):228-230.[6]张秀珠,王树录.布地奈德、沙丁胺醇、异丙托溴铵治疗慢阻肺急性加重期的疗效及对通气功能、凝血指标的影响[J].血栓与止血学,2022,28(3):721-723.[7]慢性阻塞性肺疾病急性加重诊治专家组.慢性阻塞性肺疾病急性加重诊治中国专家共识(2023年修订版)[J].国际呼吸杂志,2023,43(2):132-149.[8]孙步伟,杨文锋.异丙托溴铵联合布地奈德对慢阻肺合并呼吸衰竭患者CAT评分、血清PCT水平及肺功能的影响[J].武警后勤学院学报(医学版),2021,30(2):42-45.[9]缪志龙,王缇,丁小星,等.麻龙定喘汤联合布地奈德、噻托溴铵对哮喘-慢阻肺重叠综合征患者的临床疗效[J].中成药,2021,43(12):3562-3565.[10]张晓春,赵品勇,周燕萍,等.沙丁胺醇联合布地奈德治疗哮喘-慢阻肺重叠综合征临床疗效及对患者炎症免疫功能影响观察[J].中国药师,2020,23(12):2412-2415.[11]李颖,陈霞,郎桂媛,等.小青龙汤加减联合布地奈德、噻托溴铵吸入治疗对哮喘慢阻肺重叠综合征患者肺功能、FeNO和气道重塑的影响[J].辽宁中医药大学学报,2021,23(3):179-182.[12]谭德伦,杨震,夏明成.异丙托溴铵联合布地奈德福莫特罗对哮喘-慢阻肺重叠血清炎症因子及肺功能的影响[J].湖南师范大学学报(医学版),2020,17(1):172-174.[13]张华根,曾伟坚,彭贵霞,等.布地奈德福莫特罗粉吸入剂联合孟鲁司特钠在哮喘-慢阻肺重叠综合征患者治疗中的应用研究[J].实用药物与临床,2018,21(7):811-814.[14]申霖.布地奈德福莫特罗粉吸入剂联合噻托溴铵对慢阻肺合并支气管哮喘患者ACT评分、肺功能及血清T淋巴细胞亚群水平的影响[J].医药论坛杂志,2021,42(4):123-127.[15]邢振川,郭华征,高芸菲.硫酸特布他林联合布地奈德混悬液雾化吸入治疗慢阻肺急性加重期的疗效及对血清PCT、IL-6、IFN-γ水平变化的影响[J].解放军预防医学杂志,2019,37(10):20-21.[16]刘颖,薄晓霞,张亚娟.布地奈德福莫特罗、噻托溴铵、家庭无创正压通气对慢性阻塞性肺疾病患者影响的研究[J].临床肺科杂志,2018,23(8):1394-1397.[17]马天宇.小剂量布地奈德联合特布他林治疗慢性阻塞性肺疾病急性加重期对肺功能与免疫功能指标的影响[J].中华养生保健,2024,42(6):177-180.[18]边明艳,卜丽.布地格福吸入气雾剂与布地奈德福莫特罗粉吸入剂对缓解期慢阻肺患者肺功能以及生活质量影响的对照研究[J].实用药物与临床,2022,25(1):42-45.[19]许柳柳,朱洁晨,卞宏,等.布地奈德福莫特罗联合噻托溴铵吸入剂治疗慢阻肺疗效及对CRP、SaO2、PH水平影响[J].现代生物医学进展,2020,20(22):4369-4372.[20]闫平.布地奈德福莫特罗粉吸入剂联合孟鲁司特钠对哮喘慢阻肺重叠综合征患者的影响[J].医药论坛杂志,2022,43(13):93-96.[21]郑君亮.孟鲁司特钠联合布地奈德福莫特罗治疗慢性阻塞性肺疾病稳定期的疗效及对炎性因子、可溶性机制裂解素2蛋白表达的影响[J].中国基层医药,2020,27(8):922-926.[22]徐东波,李艳静,李站领,等.小青龙汤联合西药治疗哮喘-慢阻肺重叠综合征疗效及对血清炎症因子、肺功能的影响[J].现代中西医结合杂志,2021,30(29):3233-3237.

相似文献/References:

[1]李凤利,陈 伟,张 林.不同剂量沐舒坦在肺癌围术期的肺功能保护作用[J].医学信息,2018,31(07):128.[doi:10.3969/j.issn.1006-1959.2018.07.043]
　LI Feng-li,CHEN Wei,ZHANG Lin.Protective Effects of Different Doses of Ambroxol on Lung Function in Patients with Lung Cancer during Perioperative Period[J].Journal of Medical Information,2018,31(13):128.[doi:10.3969/j.issn.1006-1959.2018.07.043]
[2]马建娟.布地奈德联合异丙托溴铵雾化治疗COPD 急性加重期的效果评价[J].医学信息,2018,31(07):141.[doi:10.3969/j.issn.1006-1959.2018.07.048]
　MA Jian-juan.Efficacy Evaluation of Budesonide Combined with Ipratropium Bromide in Treatment of Acute Exacerbation of COPD[J].Journal of Medical Information,2018,31(13):141.[doi:10.3969/j.issn.1006-1959.2018.07.048]
[3]罗玉霞.舒适护理在布地奈德联合氨溴索雾化吸入治疗 慢阻肺急性发作患者的效果分析[J].医学信息,2018,31(12):179.[doi:10.3969/j.issn.1006-1959.2018.12.058]
　LUO Yu-xia.Analysis of the Effect of Comfortable Nursing in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Patients with Aerosolized Inhalation of Budesonide and Ambroxol[J].Journal of Medical Information,2018,31(13):179.[doi:10.3969/j.issn.1006-1959.2018.12.058]
[4]张明荣.孟鲁司特钠联合布地奈德治疗小儿哮喘的临床疗效分析[J].医学信息,2018,31(13):131.[doi:10.3969/j.issn.1006-1959.2018.13.038]
　ZHANG Ming-rong.Clinical Analysis of Montelukast Sodium Combined with Budesonide in the Treatment of Childhood Asthma[J].Journal of Medical Information,2018,31(13):131.[doi:10.3969/j.issn.1006-1959.2018.13.038]
[5]邱亚双.辛夷鼻炎丸联合布地奈德治疗变应性鼻炎的临床观察[J].医学信息,2019,32(03):158.[doi:10.3969/j.issn.1006-1959.2019.03.052]
　QIU Ya-shuang.Clinical Observation of Xinyi Biyan Wan Combined with Budesonide in Treating Allergic Rhinitis[J].Journal of Medical Information,2019,32(13):158.[doi:10.3969/j.issn.1006-1959.2019.03.052]
[6]王 瑜.布地奈德混悬液联合特布他林治疗小儿哮喘的效果[J].医学信息,2022,35(12):184.[doi:10.3969/j.issn.1006-1959.2022.12.047]
　WANG Yu.Effect of Budesonide Suspension Combined with Terbutaline in the Treatment of Pediatric Asthma[J].Journal of Medical Information,2022,35(13):184.[doi:10.3969/j.issn.1006-1959.2022.12.047]
[7]王 雪,章 晔,李宝华.孟鲁斯特钠片与异丙托溴铵和布地奈德混悬液雾化吸入对小儿呼吸道感染性咳嗽的临床疗效[J].医学信息,2022,35(12):190.[doi:10.3969/j.issn.1006-1959.2022.12.049]
　WANG Xue,ZHANG Ye,LI Bao-hua.Clinical Effect of Montelukast Sodium Tablets Combined with Ipratropine Bromide and Budesonide Mixed Suspension Atomization Inhalation on Children with Respiratory Tract Infection Cough[J].Journal of Medical Information,2022,35(13):190.[doi:10.3969/j.issn.1006-1959.2022.12.049]
[8]周 佳,柴明思.布地奈德、异丙托溴铵气雾剂联合雾化吸入治疗对肺气肿患者肺功能及血液相关指标的影响[J].医学信息,2019,32(09):151.[doi:10.3969/j.issn.1006-1959.2019.09.050]
　ZHOU Jia,CHAI Ming-si.Effects of Budesonide and Ipratropium Bromide Aerosol Combined with Nebulized Inhalation on Pulmonary Function and Blood Related Indexes in Patients with Emphysema[J].Journal of Medical Information,2019,32(13):151.[doi:10.3969/j.issn.1006-1959.2019.09.050]
[9]韦春峥,莫 彬,莫善圆,等.孟鲁司特钠联合布地奈德治疗儿童支气管哮喘合并变应性鼻炎的临床效果[J].医学信息,2019,32(20):142.[doi:10.3969/j.issn.1006-1959.2019.20.044]
　WEI Chun-zheng,MO Bin,MO Shan-yuan,et al.Clinical Effect of Montelukast Sodium Combined with Budesonide in the Treatment of Children with Bronchial Asthma Complicated with Allergic Rhinitis[J].Journal of Medical Information,2019,32(13):142.[doi:10.3969/j.issn.1006-1959.2019.20.044]
[10]刘江海.异丙托溴铵雾化吸入治疗慢阻肺急性加重期的临床疗效[J].医学信息,2019,32(20):150.[doi:10.3969/j.issn.1006-1959.2019.20.047]
　LIU Jiang-hai.Clinical Efficacy of Ipratropium Bromide Inhalation in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Journal of Medical Information,2019,32(13):150.[doi:10.3969/j.issn.1006-1959.2019.20.047]

更新日期/Last Update: 1900-01-01